3 terminated. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 3 |
Follow Abdominal Pain: new trials by email Literature Review of Abdominal Pain trials Research Report on Abdominal Pain
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation OPS-2071, Placebo - Crohn's Disease | Phase 2 | Terminated | Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | 2020-02-25 | 2021-06-15 |
| Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D) Olorinab, Placebo - Irritable Bowel Syndrome | Phase 2 | Terminated | Arena Pharmaceuticals | 273 | 2019-07-24 | 2025-01-30 |
| Milnacipran (Savella) in Irritable Bowel Syndrome (IBS) Milnacipran, Placebo - Irritable Bowel Syndrome | Phase 2 | Terminated | Spencer Dorn, MD, MPH | 2 | 2012-04-01 | 2017-04-13 |
Irritable Bowel Syndrome (2) · Crohn Disease (1) · Diarrhea (1) · Inflammation (1) · Inflammatory Bowel Diseases (1)
Digestive System Diseases (3) · Gastrointestinal Diseases (3) · Intestinal Diseases (3) · Neurologic Manifestations (3) · Pain (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Signs and Symptoms, Digestive (3) · Colonic Diseases (2) · Colonic Diseases, Functional (2) · Gastroenteritis (1) · Pathologic Processes (1)
Milnacipran (1) · olorinab (1)
Arena Pharmaceuticals (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Spencer Dorn, MD, MPH (1)
United States (3) · Poland (1)
Arena CT.gov Administrator (1) · Spencer D Dorn, MD, MPH (1)
2019 (1)